days two through five.3 The approval occurred ahead of the Prescription Drug User Fee Act (PDUFA) action date of June 16, 2026. “The FDA approval of XOCOVA provides an important new approach to preventing COVID-19, which continues to impact lives....
AVD for previously untreated Stage III or IV cHL in adults and pediatric patients 12 years and older, granted in March 2026.2 Earlier this year, the EC also approved Opdivo in combination with brentuximab vedotin for the treatment of children 5...
plan to progress the current IIT and file an IND application in China to conduct a Phase 1 clinical trial later in 2026. Jason C. Foster, CEO, Ori Biotech, said: “This is the milestone we’ve been building toward for the last 7 years — IRO®...
The 9th Annual Digi-Tech Pharma & AI conference, a premier Pharmaceutical Technology Conference, brings with it even more interactive sessions, expert speakers, senior professionals and decision makers from leading pharma, bio-tech and healthcare...
benefit from extended endocrine therapy beyond five years.2,3 More information on these findings will be presented at the 2026 ASCO Annual Meeting on June 1. The data come from a new analysis of the ongoing BCI Registry Study, which evaluates how...
builds on Aspera’s inaugural ADAR1p150 crystallization experiment, which launched aboard SpaceX Crew-12 in February 2026. Funded through NASA’s In Space Production Applications (InSPA) Phase 2 award, the work uses Redwire Corporation’s...
included patients with carcinoma in situ (CIS), with or without papillary tumors (±Ta/T1). The findings – presented at the 2026 American Urological Association (AUA) Annual Meeting and scheduled for publication in Translational Andrology and...
Pathobiology 2026 – May 16-19, 2026, in Fort Myers, Florida. Similar to the past two Annual Meetings, Pathobiology 2026 will be a stand-alone meeting that will leverage our society’s unique strengths in the understanding of cellular and molecular...
CCRN, CNRN, SCRN, FAHA, FNCS, FCCM, will speak as part of NeurOptics' in-booth clinical education programming at AACN NTI 2026, May 17–20, in San Diego. NeurOptics will be exhibiting in Booth #1616. Olson will present "Evidence-Based Practice in...
safeguarded by 10 patents and backed by 17 peer-reviewed studies conducted since 2006, with the latest published in March 2026. Its efficacy at a daily dose of just 25 mg has been demonstrated in multiple human clinical trials, highlighting its...
its clinically supervised weight-loss program to support earlier intervention and more accessible preventive care. As of 2026, the program has demonstrated strong outcomes: 85% of patients lost weight within their first three months About...
standards. U.S. sales of Tranexamic Acid Injection were approximately $30.2 million for the twelve months ending in March 2026, with ready-to-use presentations accounting for approximately $15 million of total sales.1 Indications Tranexamic Acid...
2nd Annual MaxPotent Pharma Summit – a leading international platform bringing together senior executives, regulatory authorities, technology providers, and pharmaceutical innovators dedicated to advancing the future of Highly Potent Active...
(semaglutide) tablets 25 mg for use in adults with type 2 diabetes. The company expects an FDA decision by the end of 2026. Do not use Ozempic® if: you or any of your family have ever had MTC, or if you have an endocrine system condition called...
including required anti-trust clearance and other customary conditions, and is expected to close by end of Q2 – early Q3 2026. Lazard is acting as financial advisor to UCB, and Covington & Burling LLP is serving as legal counsel to UCB. Jefferies...
Industry Leaders will be available on newsstands April 28. The full list is available now at: https://time.com/article/2026/04/27/time100-companies-health/ About Sprout Pharmaceuticals Sprout Pharmaceuticals is leading a revolution in women's...
of Defense (DoD) and will begin commercial deployment of its FDA-cleared wound treatment, Hemastyl®, starting May 1, 2026. Clinical training across VA and DoD facilities will begin May 1, marking the company's first large-scale entry into...
and spinal cord, at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 11–15, 2026 in Boston, MA. Data presented by Apertura at ASGCT show that TfR1 CapX can be manufactured at clinically relevant scale,...
New Drug Application (sNDA) to the FDA in 2H26 based on the ReSPECT results. Mundipharma expects an EMA submission in Q3, 2026. About rezafungin Rezafungin is a next-generation echinocandin approved for the treatment of candidaemia and invasive...
indication of obesity. Topline data from the Phase II study for the treatment of T2D are expected in the third quarter of 2026. "ASC30 has potential to be the best-in-class oral small molecule GLP-1 for obesity, evidenced by its efficacy and...
